Vyome Holdings HIND 深 沪
等待开盘 10-17 09:30:00 美东时间
1.90
-0.010
-0.52%
华盛通- 最 高1.90
- 今 开1.89
- 成交量 6484股
- 最 低 1.87
- 昨 收 1.91
- 总市值 1333.52万
- 52周最高 6.56
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 1.75
- 委 比 61.24%
- 总股本 701.85万
- 历史最高 22.40
- 量 比 1.23
- 振 幅 1.57%
- 历史最低 0.018
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vyome appoints new CFO
Vyome Holdings (HIND) appointed Jerry Leonard, CPA, MBA, as chief financial officer, effective September 1, 2026. Leonard succeeds Robert Dickey IV, who had served as interim CFO since August 2025. Le...
09-14 20:12
Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025
Finance executive with more than 25 years of experience brings extensive expertise in public company financial management, SEC reporting, financial operations, and governance Vyome Holdings, Inc. (NASDAQ:HIND) ("Vyome" or the "Company"), a clinical-stage biopharmaceutical company focused on developi...
09-14 20:06
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Vyome Appoints Jerry Leonard As CFO On August 27, 2026
On August 27, 2026, the board of directors (the "Board") of Vyome Holdings, Inc. (the "Company") appointed Jerry Leonard as the Company’s Chief Financial Officer. In connection with Mr. Leonard’s appointment, the Board, upon the recommendation of the compensation committee of the Board, approved a C...
08-29 04:40
Vyome Holdings, Inc. reports Q2 results
Vyome Holdings, Inc. press release (HIND): Q2 Net loss attributable to common shareholders for the quarter ended June 30, 2026, was approximately $720,000, or approximately $0.10 per basic and dilute...
08-26 03:53
Vyome Holdings Reports Data On Its Phase 2 Investigator Initiated Trial Results, Preclinical Data Of VT-1953 To Treat Symptoms Of Malignant Fungating Wounds At American Association For Cancer Research Annual Meeting
Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of
04-22 20:05
Vyome Holdings To Present Full Phase 2 Investigator Initiated Study Results And Preclinical Data Supporting Efficacy And Safety Of VT-1953 As Potential Treatment For Malodor And Other Symptoms Of MFW At 2026 AACR
Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer ResearchVyome Holdings, Inc. ("Vyome")
04-06 20:06
美股夜盘 | Urgent.ly Inc.涨160.59%，STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%
Urgent.ly Inc.涨160.59%；STRATS Trust for Allstate Corp Utd Sts Cellular Strats 6.375涨102.02%；Click Holdings Limited Class A涨53.06%
03-16 10:02
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a current VT-1953
02-11 20:07
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers ENvue Medical (NASDAQ:FEED) stock moved upwards by 19.0% to $1.25 duri...
01-28 20:05
